成都先导药物开发股份有限公司关于募集资金投资项目延期的公告

Group 1 - The company announced a delay in the fundraising investment projects, specifically for the "New Molecular Design, Construction and Application Platform Construction Project" and the "New Drug Research Center Construction Project," extending the completion date to March 2028 [2][9] - The total amount raised in the initial public offering was approximately RMB 834.75 million, with a net amount of RMB 746.01 million after deducting issuance fees [2][5] - The company has adhered to relevant regulations regarding the management of raised funds and has established a dedicated account for fund storage [3][10] Group 2 - The delay in the fundraising investment projects is due to the complexity and rigor of the engineering projects, requiring careful consideration of the company's future planning and technological characteristics [6][7] - The company has confirmed that the delay will not change the investment subjects, methods, purposes, or scales of the fundraising projects, ensuring no substantial impact on the implementation of these projects [8][10] - The company will continue to comply with legal regulations and will manage the construction progress of the fundraising investment projects effectively [7][10] Group 3 - The company has implemented an employee stock ownership plan, with 107 employees participating and a total subscription amount of RMB 1.44 million, corresponding to 123,870 shares [13][14] - The shares were transferred to the employee stock ownership plan account at a price of RMB 11.66 per share, representing 0.31% of the company's total share capital [14] - The plan has a duration of 48 months, with shares unlocking in two phases based on performance assessments [14]